Pioneering first-in-class treatments for patients with thromboinflammatory diseases

Aplagon is a clinical stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases. These include thrombotic, vascular occlusion related cardiovascular diseases, which cause around 1 in 4 deaths worldwide.

Thromboinflammation is a key driver for the progression of cardiovascular diseases, leading to blood vessel occlusions and organ damage.

APAC Therapeutic

Aplagon’s therapeutic asset is known as APAC, a unique vascular injury targeting, triple action antiplatelet (AP), anticoagulant (AC) and anti-inflammatory molecule, designed to combat a wide range of thromboinflammatory diseases.

Learn More

Latest News

Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia 12 March 2026
Aplagon Announces EUR 7 Million Financing to Advance its APAC Therapeutic for Thrombo-Inflammatory Diseases into Phase 2A Clinical Trials 3 February 2025